surpassing LVMH on the back of soaring demand for Ozempic and Wegovy. Today, the Danish company has lost its grip on the anti-obesity market it carved out. The company has lost market share amid ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Coca-Cola remains resilient amid GLP-1 health trends and geopolitical risks, with proactive innovation and a diversified ...

Eli Lilly is a pharma player, but it offers the growth of a tech stock thanks to its weight loss drugs portfolio. The weight ...

Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...

Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Semaglutide Market Size, Share & Trends Analysis Report by Product (Ozempic ... healthcare infrastructure investments and increasing awareness ...

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

Investing.com -- The European Medicines Agency’s (EMA) safety committee, PRAC, said Friday that it has concluded that ...

(Reuters) -Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to ...

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...